Carna Biosciences, Inc.
4572.T · JPX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | ¥5,373,009 | ¥8,769,644 | ¥7,081,017 | ¥13,990,494 |
| - Cash | ¥2,108,484 | ¥2,889,101 | ¥3,379,048 | ¥3,817,834 |
| + Debt | ¥61,341 | ¥182,971 | ¥300,390 | ¥539,887 |
| Enterprise Value | ¥3,325,866 | ¥6,063,514 | ¥4,002,359 | ¥10,712,547 |
| Revenue | ¥636,235 | ¥1,625,889 | ¥1,386,748 | ¥2,017,529 |
| % Growth | -60.9% | 17.2% | -31.3% | – |
| Gross Profit | ¥465,693 | ¥1,450,596 | ¥1,215,198 | ¥1,882,142 |
| % Margin | 73.2% | 89.2% | 87.6% | 93.3% |
| EBITDA | -¥2,139,774 | -¥1,091,782 | -¥1,284,279 | -¥509,408 |
| % Margin | -336.3% | -67.1% | -92.6% | -25.2% |
| Net Income | -¥2,178,576 | -¥1,152,895 | -¥1,349,539 | -¥534,474 |
| % Margin | -342.4% | -70.9% | -97.3% | -26.5% |
| EPS Diluted | -121.64 | -68.62 | -99.1 | -42.1 |
| % Growth | -77.3% | 30.8% | -135.4% | – |
| Operating Cash Flow | -¥1,374,806 | -¥1,677,464 | -¥708,390 | -¥1,536,612 |
| Capital Expenditures | -¥13,060 | -¥11,530 | -¥126,001 | -¥41,677 |
| Free Cash Flow | -¥1,387,866 | -¥1,688,994 | -¥834,391 | -¥1,578,289 |